Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)

NCT07457918 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

600

Enrollment

INDUSTRY

Sponsor class

Conditions

Common Warts (Verruca Vulgaris)
Common Warts
Human Papilloma Virus (HPV)
Warts

Interventions

COMBINATION_PRODUCT: Cantharidin

Sponsor

Verrica Pharmaceuticals Inc.

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]